| Maverakis, Emanual |
NCT04128176: Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid |
|
|
| Withdrawn | 3 | 15 | US | Rituximab combined with Omalizumab, Xolair | University of California, Davis | Bullous Pemphigoid | 05/23 | 11/23 | | |
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color |
|
|
| Active, not recruiting | 3 | 80 | US | Lebrikizumab, LY3650150, DRM06 | Eli Lilly and Company | Atopic Dermatitis | 05/24 | 02/25 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
NCT05040204: The Effects of Dietary Supplementation on Serum Protein Glycosylation |
|
|
| Recruiting | 1 | 44 | US | Monosaccharide Powder, Placebo Comparator | University of California, Davis, National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Healthy | 05/25 | 09/25 | | |
NCT04466761: Ascending Glycan Dietary Supplementation in Healthy Adults |
|
|
| Terminated | 1 | 14 | US | Monosaccharide Powder, Placebo Comparator | University of California, Davis | Healthy Individuals | 08/24 | 08/24 | | |
NCT03437005: Alternation in the Human Microbiome With Commonly Used Topical Medications |
|
|
| Recruiting | 1 | 24 | US | Desonide 0.05%, Ketoconazole 2% | University of California, Davis | Healthy | 09/26 | 09/26 | | |
NCT00368615: Characterization of the Melanoma-Specific Immune Response |
|
|
| Recruiting | N/A | 20 | US | | University of California, Davis | Melanoma | 08/24 | 08/24 | | |
| Evans, Tanya |
ADapt, NCT05369403: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab |
|
|
| Active, not recruiting | 3 | 120 | US | Lebrikizumab, LY3650150, DRM06 | Eli Lilly and Company | Atopic Dermatitis | 01/24 | 02/25 | | |
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color |
|
|
| Active, not recruiting | 3 | 80 | US | Lebrikizumab, LY3650150, DRM06 | Eli Lilly and Company | Atopic Dermatitis | 05/24 | 02/25 | | |
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight |
|
|
| Recruiting | 3 | 250 | US | Ixekizumab, LY2439821, Tirzepatide, LY3298176 | Eli Lilly and Company | Psoriasis, Obesity | 12/25 | 05/26 | | |
